Berenberg Bank analyst Calum Battersby maintained a Buy rating on Spectris (SXS – Research Report) yesterday and set a price target of p3,180.00. The company’s shares closed yesterday at p2 ...

Spectris plc has a fifty-two week low of GBX 2,370 ($29.29) and a fifty-two week high of GBX 3,730 ($46.09). The company has a debt-to-equity ratio of 4.37, a current ratio of 2.36 and a quick ...

CAMBRIDGE, Mass., February 11, 2025--(BUSINESS WIRE)--Cognito Therapeutics, a neurotechnology company advancing disease-modifying therapies to treat CNS diseases, today announced the publication ...

The study, titled “CSF Proteomics Reveals Changes in Myelin and Synaptic Biology Following Spectris™ Treatment,” offers compelling evidence of Spectris™’ ability to modulate core ...

Jefferies analyst Andrew Douglas has maintained their bullish stance on SXS stock, giving a Buy rating on January 21. Andrew Douglas’s rating is based on the recent trading update from Spectris ...

The study, titled "CSF Proteomics Reveals Changes in Myelin and Synaptic Biology Following Spectris™ Treatment," offers compelling evidence of Spectris™’ ability to modulate core biological pathways ...

Using the 2 Stage Free Cash Flow to Equity, Spectris fair value estimate is UK£42.80 Spectris is estimated to be 30% undervalued based on current share price of UK£29.82 The UK£31.05 analyst ...

Shares in Spectris have delivered a thoroughly disappointing return since this column first recommended them in November 2022. The precision instruments business, which provides data and insights ...

(Sharecast News) - Precision instruments supplier Spectris said it expects to beat market expectations with its 2024 results. In a brief trading update on Thursday, the company said its fourth ...